Evidence map›Paper›PMID 31555451›Full record

ArticleNeuro-oncology practice2019

Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival.

Christopher H Chapman, Jared H Hara, Annette M Molinaro, Jennifer L Clarke, Nancy Ann Oberheim Bush, Jennie W Taylor, Nicholas A Butowski, Susan M Chang, Shannon E Fogh, Penny K Sneed and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Re-irradiation with stereotactic radiotherapy for recurrent high-grade glial tumors.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher H ChapmanDepartment of Radiation Oncology, University of California San Francisco.ORCID 0000-0003-1848-1490
Jared H HaraJohn A. Burns School of Medicine, University of Hawaii, Honolulu.
Annette M MolinaroDepartment of Neurological Surgery, University of California San Francisco, USA.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California San Francisco, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California San Francisco, USA.
Jennie W TaylorDepartment of Neurological Surgery, University of California San Francisco, USA.
Nicholas A ButowskiDepartment of Neurological Surgery, University of California San Francisco, USA.
Susan M ChangDepartment of Neurological Surgery, University of California San Francisco, USA.
Shannon E FoghDepartment of Radiation Oncology, University of California San Francisco.
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco.
Jean L NakamuraDepartment of Neurology, University of California San Francisco.
David R RaleighDepartment of Radiation Oncology, University of California San Francisco.
Steve E BraunsteinDepartment of Radiation Oncology, University of California San Francisco.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundOptimal techniques and patient selection for salvage reirradiation of high-grade glioma (HGG) are unclear. In this study, we identify prognostic factors for freedom from progression (FFP) and overall survival (OS) after reirradiation, risk factors for high-grade toxicity, and validate clinical prognostic scores.

methodsA total of 116 patients evaluated between 2000 and 2018 received reirradiation for HGG (99 WHO grade IV, 17 WHO grade III). Median time to first progression after initial therapy was 10.6 months. Salvage therapies before reirradiation included surgery (31%) and systemic therapy (41%). Sixty-five patients (56%) received single-fraction stereotactic radiosurgery (SRS) as reirradiation. The median biologically effective dose (BED) was 47.25 Gy, and the median planning target volume (PTV) was 4.8 cc for SRS and 95.0 cc for non-SRS treatments. Systemic therapy was given concurrently to 52% and adjuvantly to 74% of patients.

resultsMedian FFP was 4.9 months, and median OS was 11.0 months. Significant multivariable prognostic factors for FFP were performance status, time to initial progression, and BED; for OS they were age, time to initial progression, and PTV volume at recurrence. High-grade toxicity was correlated to PTV size at recurrence. Three-level prognostic scores were generated for FFP and OS, with cross-validated receiver operating characteristic area under the curve (AUC) of 0.640 and 0.687, respectively.

conclusionsClinical variables at the time of reirradiation for HGG can be used to prognosticate FFP and OS.

Indexed as

glioblastomagliomaprognosisrecurrencereirradiation

Identifiers

PMID31555451
PMCPMC6753361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.